<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Marrow cells from patients with higher-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) exhibit constitutive nuclear factor (NF)-κB activation </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:chebi fb="0" ids="52726">proteasome inhibitor</z:chebi>, <z:chebi fb="0" ids="52717">bortezomib</z:chebi>, has limited efficacy as a single agent in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>Its activity on leukaemic cell lines is potentiated by chemotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>We treated 43 higher-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with <z:chebi fb="0" ids="52717">bortezomib</z:chebi> (1·5 mg/m(2) , days 1, 4, 8 and 11) and low dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (LDAC; 10 mg/m(2) , then 20 mg/m(2) from days 1-14), every 28 d for four cycles </plain></SENT>
<SENT sid="4" pm="."><plain>Median follow-up was 29·7 months </plain></SENT>
<SENT sid="5" pm="."><plain>Responses were seen in 12 of the 43 patients (28%), including complete response (CR, n = 1), marrow-CR (n = 3), partial response (PR, n = 5) and haematological improvement (HI, n = 3) </plain></SENT>
<SENT sid="6" pm="."><plain>Responses were seen in 12 (36%) of the 33 previously untreated patients (11% CR, 13% PR, 2·5% HI), compared to none in the 12 previously treated patients (P &lt; 0·01) </plain></SENT>
<SENT sid="7" pm="."><plain>Responders had better overall survival (median 18·2 vs. 10 months) </plain></SENT>
<SENT sid="8" pm="."><plain>One CR and 3 marrow-CRs were seen in patients with complex karyotypes </plain></SENT>
<SENT sid="9" pm="."><plain>Main toxicity was haematological, responsible for <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> in six patients and <z:mp ids='MP_0001914'>bleeding</z:mp> in 3 </plain></SENT>
<SENT sid="10" pm="."><plain>Three patients with Grade 1-2 pre-treatment haematotoxicity developed Grade 3-4 toxicity </plain></SENT>
<SENT sid="11" pm="."><plain><z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">Neuropathy</z:e> was seen in 12% of patients </plain></SENT>
<SENT sid="12" pm="."><plain>The addition of <z:chebi fb="0" ids="52717">bortezomib</z:chebi> to LDAC in higher-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> may improve results obtained with LDAC alone, especially in patients with unfavourable karyotypes </plain></SENT>
</text></document>